HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improved survival in acute necrotizing pancreatitis despite limiting the indications for surgical debridement.

AbstractOBJECTIVE:
To reassess our criteria for the stratification of attacks of acute pancreatitis, and indications for operation in patients with necrotising pancreatitis.
DESIGN:
Retrospective analysis of casenotes.
SETTING:
University Hospital, Germany.
SUBJECT:
341 Consecutive patients who presented with a first attack of acute pancreatitis between December 1979 and January 1991.
MAIN OUTCOME CRITERIA:
Morbidity and mortality in relation to clinical (Ranson, Kümmerle, Goris) and radiological (Balthazar) criteria.
RESULTS:
78 Patients developed necrotising pancreatitis judged radiologically. Mortality was 15/38 (39%) in the period 1980-85 and 6/40 (15%) in the period 1986-1990. During the first period patients were operated on if their unfavourable clinical signs did not start to resolve within 72 hours, whereas in the second period operation was restricted to those patients who developed signs of multiple organ failure. This policy resulted in the number of operations being reduced from 26/38 (68%) to 17/40 (42%), respectively (p = 0.03).
CONCLUSION:
Our data support the policy of restricting surgical debridement in necrotising pancreatitis to those patients who develop signs of multiple organ failure.
AuthorsT Foitzik, E Klar, H J Buhr, C Herfarth
JournalThe European journal of surgery = Acta chirurgica (Eur J Surg) Vol. 161 Issue 3 Pg. 187-92 (Mar 1995) ISSN: 1102-4151 [Print] England
PMID7599297 (Publication Type: Journal Article)
Topics
  • Acute Disease
  • Acute Kidney Injury (etiology)
  • Adult
  • Aged
  • Cardiac Output, Low (etiology)
  • Debridement
  • Germany (epidemiology)
  • Humans
  • Multiple Organ Failure (etiology, surgery)
  • Necrosis
  • Pancreatitis (diagnostic imaging, etiology, mortality, surgery)
  • Radiography
  • Respiratory Insufficiency (etiology)
  • Retrospective Studies
  • Sepsis (microbiology)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: